We provide you with 20 years of free, institutional-grade data for GRTS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GRTS. Explore the full financial landscape of GRTS stock.
| Reported Date | CIK | Ticker | Type |
|---|
Gritstone Oncology, Inc(NASDAQ:GRTS) 
Gritstone Oncology, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, includi...
Website: http://gritstoneoncology.com
Founded: 2015
Full Time Employees: 177
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about GRTS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.